Table 2 Zone of clearance (mm) and phenotypic resistance determination for clinical Pseudomonas aeruginosa isolates.
| Â | Pa-3 | Pa-8 | ATCC 27853 | ||
|---|---|---|---|---|---|
Antibiotic | Kirby–Bauer (mm) | Interpretation | Kirby–Bauer (mm) | Interpretation | Kirby–Bauer (mm) |
Delafloxacin | 6 | Resistant | 6 | Resistant | 23–29 |
Ceftazidime | 6 | Resistant | 6 | Resistant | 22–29 |
Cefepime | 6 | Resistant | 6 | Resistant | 25–31 |
Meropenem | 6 | Resistant | 6 | Resistant | 27–33 |
Imipenem | 6 | Resistant | 25 | Sensitive | 20–28 |
Piperacillin/tazobactam | 24 | Sensitive | 19 | Intermediate | 25–33 |
Ceftolozane/tazobactam | 6 | Resistant | 29 | Sensitive | 25–31 |
Ceftazidime/avibactam | 6 | Resistant | 26 | Sensitive | 25–31 |
Ciprofloxacin | 6 | Resistant | 6 | Resistant | 25–33 |
Levofloxacin | 6 | Resistant | 6 | Resistant | 19–26 |
Gentamicin | 6 | Resistant | 6 | Resistant | 17–23 |
Amikacin | 6 | Resistant | 17 | Sensitive | 18–26 |
Trimethoprim/sulfamethoxazole | 6 | NA | 6 | NA | — |
Fosfomicin | 12 | Resistant | 15 | Intermediate | — |
Colistin | 13 | Sensitive | 15 | Sensitive | 11–17 |
Aztreonam | 17 | Intermediate | 16 | Intermediate | 23–29 |
Doxycycline | 6 | NA | 6 | NA | — |
Minocycline | 6 | NA | 6 | NA | — |
Tigecycline | 6 | NA | 6 | NA | 9–13 |
Nitrofurantoin | 6 | NA | 6 | NA | — |
Carbapenem inactivation assay | 14 | Positive | 27 | Positive | — |
